Dose not to be repeated no earlier than 3 days. For treatment of familial Mediterranean fever: Do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairmentFor treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Do not coadminister unless potential benefits of prednisone outweigh the risks of systemic corticosteroid adverse effects.Dose adjustment not established; monitor and adjust sirolimus as indicatedInitiate with an adjusted dose of immunosuppressant to account for potential increased concentrations of the immunosuppressant and monitor for toxicities. Ritonavir and its structural analogue cobicistat are HIV treatment-boosting agents that potently inhibit the cytochrome P450 3A (CYP3A) enzyme group in the liver 2-4 in order to prolong the action of some antiretroviral medications. Corticosteroids are cytochrome P450 3A4 substrates, which have been associated with toxicities in patients receiving cytochrome P450 3A4 inhibitors such as human immunodeficiency virus protease inhibitors. For treatment of familial Mediterranean fever: Do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Interactions between Immune modulators and AntiretroviralsTherapeutic drug monitoring of immunosuppressant is recommended. Do not coadminister in patients with hepatic or renal impairment.For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in … For prophylaxis of gout, reduce colchicine dosage to 0.3 mg QD if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg QOD if on 0.6 mg QD prior to PI therapy. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in … Dose not to be repeated no earlier than 3 days. For prophylaxis of gout, reduce colchicine dosage to 0.3 mg QD if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg QOD if on 0.6 mg QD prior to PI therapy. to characterize the influence of low-dose ritonavir on prednisolone pharmacokinetics in healthy subjects. J Acquir Immune Defic Syndr 2008; 48: 561-66. Do not coadminister in patients with hepatic or renal impairment.For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Ten HIV-seronegative volunteers were given single oral doses of prednisone, 20 mg, before (baseline) and after receiving ritonavir, 200 mg, twice daily for 4 and 14 days. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. 426: Busse KH, Formentini E, Alfaro RA, Kovacs JA and Penzak SR. Dose not to be repeated no earlier than 3 days. For treatment of familial Mediterranean fever: Do not exceed colchicine 0.6 mg once daily or 0.3 mg BID.

Do not coadminister in patients with hepatic or renal impairment. Consider alternative corticosteroid for long-term use.Use with caution with atazanavir; use with atazanavir/ritonavir is not recommended unless the potential benefit outweighs the riskUse with caution; use with darunavir/ritonavir is not recommended unless the potential benefit outweighs the risk Consider using alternative corticosteroid such as beclomethasoneConsider using alternative corticosteroid such as beclomethasoneNo dose adjustment necessary. Do not coadminister in patients with hepatic or renal impairment.For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose not to be repeated no earlier than 3 days.